AuthorisedTherapeutic exploratory (Phase II)Interventional

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

This research is looking into a new treatment called GIA632 for adults who have non-segmental vitiligo. This type of vitiligo causes patches of skin to lose their colour. The study will compare GIA632 to a 'dummy' treatment (placebo) to see how effective and safe it is. Researchers want to find out how much the skin repigments, meaning how much colour returns to the white patches. They'll also be carefully checking for any side effects. This is a Phase II study, which means it's one of the earlier steps in developing a new medicine, focusing on finding the right dose and confirming its effects.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Novartis Pharma AG

Enrolment target

Start

08 Jun 2026

Nonsegmental vitiligo

What is this study about?

This study is about a skin condition called non-segmental vitiligo. This is when patches of your skin lose their natural colour, often in many places on your body. Researchers are exploring a new medicine called GIA632 that they hope might help bring colour back to these patches.

The main goal of the study is to measure how much the vitiligo patches improve over 24 weeks – that's about six months. They will use special tools to measure changes in the amount of colour in the skin. They will also keep a close eye on any side effects or unwanted reactions to the medicine, to make sure it's safe.

The study also looks at other things, like how many people see a significant improvement, such as 50%, 75%, or even 90% of their skin colour returning. These measurements will be taken at different times over a longer period, up to 48 weeks (about 11 months), to see if the improvements last. By doing this, the researchers hope to understand if GIA632 could be a good new way to treat vitiligo.

Key takeaways

This study tests a new medicine (GIA632) for vitiligo.
It aims to see if the medicine helps bring colour back to skin patches.
The study also carefully checks for side effects and safety.
Some participants will receive a dummy medicine.
The study lasts for up to 48 weeks.
It's for adults aged 18 and over with non-segmental vitiligo.

Who may be eligible?

To join this study, you must be an adult, aged 18 years or older. Both men and women are welcome to take part.

Only people who have been diagnosed with non-segmental vitiligo can participate. This specific type of vitiligo affects various parts of the body, rather than just one area or side.

There may be other reasons why you can or cannot join the study, but these would be discussed in detail by the study team. They will ensure the study is right for you and that you meet all necessary health requirements.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have non-segmental vitiligo?
Are you able to attend regular clinic visits?
Are you willing to potentially receive a dummy medicine?
Are you keen to help research new treatments?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would be assigned to either receive the new medicine (GIA632) or a dummy medicine (placebo). Neither you nor the study doctors will know which one you are receiving during the main part of the study. You will have regular visits to the clinic where doctors and nurses will check your skin, measure any changes in your vitiligo, and ask about your general health. These assessments will involve measuring the colour of your skin patches, taking photographs, and checking for any side effects. These visits will be spread out over a period of up to 48 weeks (about 11 months) in total. There will also be a follow-up period after you stop taking the study medicine.

Potential risks and benefits

Potential benefits of joining include receiving a new, potentially effective treatment for vitiligo that isn't widely available yet, and contributing to medical research. However, there's no guarantee you'll receive the active medicine or that it will help your vitiligo. There might be side effects from taking the new medicine, which the study team will explain in detail. You are free to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (4)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany
—
Unverified
Netherlands
—
Unverified
France
—
Unverified
Italy

Common questions

What is vitiligo?

Vitiligo is a long-term skin condition where patches of skin lose their pigment, causing white areas to appear on your body.

What does 'non-segmental' vitiligo mean?

This means your vitiligo patches can appear on various parts of your body, rather than just one specific area or side.

What is a 'dummy medicine' or 'placebo'?

A placebo looks exactly like the study medicine but contains no active ingredients. It helps researchers compare the real medicine's effects.

Will I know if I'm getting the actual medicine or the placebo?

No, during the main part of the study, neither you nor the study doctors will know. This is called 'double-blind' and helps ensure fair results.

How long will the study last if I join?

The main part of the study will last around 24 weeks (6 months), with further checks extending up to about 48 weeks (11 months) in total.